Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
Liraglutide (a daily injection) resulted in an average 4-5% weight loss in 24 trials (9 937 participants), still outperforming placebo
Orforglipron is manufactured by Eli Lilly, the same pharmaceutical company that produces Mounjaro (tirzepatide), which is currently one of the most effective weight-loss treatments available in the UK
Reviews focus on expectation alignment around pricing, eligibility, communication, and pharmacy coordination as details resolve later in the process
Recent research comparing GLP-1-based therapies highlights that different medications may offer distinct benefits and trade-offs in areas such as weight loss, cardiovascular outcomes, kidney health, and body composition